BioCentury | Apr 8, 2021
Emerging Company Profile

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

...compete in indications where companies such as Horizon Therapeutics plc...
...directly with one of biotech’s rising stars, Horizon Therapeutics plc...
BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

...unresectable biliary tract cancer (BTC) with a FGFR2 fusion gene; anti-CD19 mAb Uplizna inebilizumab-cdon from Horizon Therapeutics plc...
...[18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte Corp. Insmed Inc. Pfizer Inc. Novartis AG Bayer AG Horizon Therapeutics plc...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

...discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH) and in 2019 gave Horizon Pharma...
...syrup urine disease. Danielle Golovin HemoShear Therapeutics LLC Janus Henderson Investors Adage Capital Management Takeda Pharmaceutical Co. Ltd. Suvretta Capital Management LLC Horizon Therapeutics plc...
BioCentury | Feb 6, 2021
Product Development

Genmab’s strategy for going commercial

Genmab is preparing to join the expanding ranks of biotechs taking on commercialization, and CEO Jan van de Winkel is approaching commercial strategy with the same innovative eye he’s applied to development. ...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...IPO and a drug approval along the path to value creation.It will be up to Horizon Therapeutics plc...
...1LPAR3 (EDG7; LPA3) - Lysophosphatidic acid receptor 3 Paul Bonanos Uplinza (inebilizumab, MEDI-551, MT-0551) VIB4920, MEDI4920 VIB7734, MEDI7734 Viela Bio Inc. Horizon Therapeutics plc bee2021...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...teprotumumab-trbw from Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and Horizon Therapeutics plc...
BioCentury | Dec 18, 2020
Product Development

Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

...the first of what could be more drug shortages for therapeutics that rely on contract manufacturing.Horizon Therapeutics plc...
...vaccine manufacturing.TARGETSIGF1R (CD221) – Insulin-like growth factor-1 (IGF-1) receptor Stephen Hansen Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) Catalent Inc. Horizon Therapeutics plc cov19count covid-19 Operation...
BioCentury | Dec 15, 2020
Finance

Westlake aims to strengthen L.A.-area biotech ecosystem with pair of new funds, new immunology launch

...assets. Lin and Carey worked side-by-side at Horizon Therapeutics plc...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...tech to Horizon for TepezzaHalozyme Therapeutics Inc. (NASDAQ:HALO) announced a global collaboration and license agreement granting Horizon Therapeutics plc...
...IGF-1) receptor Karen Tkach Tuzman Eli Lilly and Co. Eiger BioPharmaceuticals Inc. Halozyme Therapeutics Inc. Immunicum AB Regeneron Pharmaceuticals Inc. Kiniksa Pharmaceuticals Ltd. Horizon Therapeutics plc Schrödinger...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...By Danielle Golovin, Staff Writer Karin Rosén joined Horizon Therapeutics plc (NASDAQ:HZNP) as CSO and EVP, research and development. She...
...S.A.S. Vertex Ventures HC Voyager Therapeutics Inc. KBI Biopharma Inc. CerSci Therapeutics Inc. Krystal Biotech Inc. Reckitt Benckiser Group plc Boehringer Ingelheim GmbH Horizon Therapeutics plc Sangamo...
Items per page:
1 - 10 of 199
BioCentury | Apr 8, 2021
Emerging Company Profile

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

...compete in indications where companies such as Horizon Therapeutics plc...
...directly with one of biotech’s rising stars, Horizon Therapeutics plc...
BioCentury | Mar 25, 2021
Regulation

March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more

...unresectable biliary tract cancer (BTC) with a FGFR2 fusion gene; anti-CD19 mAb Uplizna inebilizumab-cdon from Horizon Therapeutics plc...
...[18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte Corp. Insmed Inc. Pfizer Inc. Novartis AG Bayer AG Horizon Therapeutics plc...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

...discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH) and in 2019 gave Horizon Pharma...
...syrup urine disease. Danielle Golovin HemoShear Therapeutics LLC Janus Henderson Investors Adage Capital Management Takeda Pharmaceutical Co. Ltd. Suvretta Capital Management LLC Horizon Therapeutics plc...
BioCentury | Feb 6, 2021
Product Development

Genmab’s strategy for going commercial

Genmab is preparing to join the expanding ranks of biotechs taking on commercialization, and CEO Jan van de Winkel is approaching commercial strategy with the same innovative eye he’s applied to development. ...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...IPO and a drug approval along the path to value creation.It will be up to Horizon Therapeutics plc...
...1LPAR3 (EDG7; LPA3) - Lysophosphatidic acid receptor 3 Paul Bonanos Uplinza (inebilizumab, MEDI-551, MT-0551) VIB4920, MEDI4920 VIB7734, MEDI7734 Viela Bio Inc. Horizon Therapeutics plc bee2021...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...teprotumumab-trbw from Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and Horizon Therapeutics plc...
BioCentury | Dec 18, 2020
Product Development

Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

...the first of what could be more drug shortages for therapeutics that rely on contract manufacturing.Horizon Therapeutics plc...
...vaccine manufacturing.TARGETSIGF1R (CD221) – Insulin-like growth factor-1 (IGF-1) receptor Stephen Hansen Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) Catalent Inc. Horizon Therapeutics plc cov19count covid-19 Operation...
BioCentury | Dec 15, 2020
Finance

Westlake aims to strengthen L.A.-area biotech ecosystem with pair of new funds, new immunology launch

...assets. Lin and Carey worked side-by-side at Horizon Therapeutics plc...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

...tech to Horizon for TepezzaHalozyme Therapeutics Inc. (NASDAQ:HALO) announced a global collaboration and license agreement granting Horizon Therapeutics plc...
...IGF-1) receptor Karen Tkach Tuzman Eli Lilly and Co. Eiger BioPharmaceuticals Inc. Halozyme Therapeutics Inc. Immunicum AB Regeneron Pharmaceuticals Inc. Kiniksa Pharmaceuticals Ltd. Horizon Therapeutics plc Schrödinger...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...By Danielle Golovin, Staff Writer Karin Rosén joined Horizon Therapeutics plc (NASDAQ:HZNP) as CSO and EVP, research and development. She...
...S.A.S. Vertex Ventures HC Voyager Therapeutics Inc. KBI Biopharma Inc. CerSci Therapeutics Inc. Krystal Biotech Inc. Reckitt Benckiser Group plc Boehringer Ingelheim GmbH Horizon Therapeutics plc Sangamo...
Items per page:
1 - 10 of 199